New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti-DNA.
Publication
, Journal Article
Pisetsky, DS; Rovin, BH; Lipsky, PE
Published in: Arthritis Rheumatol
March 2017
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Arthritis Rheumatol
DOI
EISSN
2326-5205
Publication Date
March 2017
Volume
69
Issue
3
Start / End Page
487 / 493
Location
United States
Related Subject Headings
- Rheumatology
- Reproducibility of Results
- Lupus Erythematosus, Systemic
- Humans
- Eligibility Determination
- DNA
- Clinical Trials as Topic
- Biomarkers
- Antirheumatic Agents
- Antibodies, Antinuclear
Citation
APA
Chicago
ICMJE
MLA
NLM
Pisetsky, D. S., Rovin, B. H., & Lipsky, P. E. (2017). New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti-DNA. Arthritis Rheumatol, 69(3), 487–493. https://doi.org/10.1002/art.40008
Pisetsky, David S., Brad H. Rovin, and Peter E. Lipsky. “New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti-DNA.” Arthritis Rheumatol 69, no. 3 (March 2017): 487–93. https://doi.org/10.1002/art.40008.
Pisetsky DS, Rovin BH, Lipsky PE. New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti-DNA. Arthritis Rheumatol. 2017 Mar;69(3):487–93.
Pisetsky, David S., et al. “New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti-DNA.” Arthritis Rheumatol, vol. 69, no. 3, Mar. 2017, pp. 487–93. Pubmed, doi:10.1002/art.40008.
Pisetsky DS, Rovin BH, Lipsky PE. New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti-DNA. Arthritis Rheumatol. 2017 Mar;69(3):487–493.
Published In
Arthritis Rheumatol
DOI
EISSN
2326-5205
Publication Date
March 2017
Volume
69
Issue
3
Start / End Page
487 / 493
Location
United States
Related Subject Headings
- Rheumatology
- Reproducibility of Results
- Lupus Erythematosus, Systemic
- Humans
- Eligibility Determination
- DNA
- Clinical Trials as Topic
- Biomarkers
- Antirheumatic Agents
- Antibodies, Antinuclear